Roche forges deal with San Diego biotech, betting on new antibiotic class

The coronavirus outbreak may be monopolizing the airwaves, but that doesn’t mean the tsunami of antibiotic resistance isn’t still incoming. But there is some encouraging progress, despite the majority of big pharma abandoning the beleaguered field of antibiotics. On Wednesday, Roche tied up with San Diego-based Forge Therapeutics in a…

Click to view original post